1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Modern Chinese Medicine Group Co. Ltd.

Modern Chinese Medicine Group Co. Ltd.

HHKEX:1643
0.31
HKD
-0.02
(-6.06%)
225.00MMarket Cap
Modern Chinese Medicine Group Co. Ltd.
HKEX:1643
(Hong Kong Exchange)

Recent

price

0.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.18
0.29
0.36
0.51
0.61
0.67
0.57
0.36
0.22
- -
Revenue per Share
0.04
0.08
0.08
0.11
0.14
0.15
0.08
0.02
-0.02
- -
Basic EPS, GAAP
-0.05
0.13
0.06
0.07
-0.02
0.19
0.01
-0.09
-0.03
- -
Free Cash Flow per Basic Share
- -
- -
0.17
- -
- -
0.01
- -
- -
- -
- -
Dividend per Share
0.13
0.21
0.11
0.22
0.56
0.7
0.79
0.81
0.69
0.81
Book Value per Share
0.13
0.21
0.11
0.22
0.56
0.7
0.79
0.81
0.69
0.81
Tangible Book Value per Share
600
600
600
600
594
600
600
600
660
600
Basic Weighted Avg Shares
106
174
219
309
361
400
344
214
145
- -
Sales/Revenue/Turnover
33.35
37.1
29.75
29.26
31.51
32.32
19.87
11.17
-11.3
- -
Operating Margin (%)
2
2
2
2
3
6
6
9
12
- -
Depreciation Expense
26
48
46
64
82
88
49
10
-14
- -
Net Income, GAAP
25.57
25.22
29.15
29.73
28.41
29.35
28.56
34.75
- -
- -
Effective Tax Rate (%)
24.31
27.8
21.14
20.6
22.67
21.98
14.18
4.52
-9.34
- -
Profit Margin (%)
59
108
50
115
248
329
388
304
292
304
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
76
124
69
135
337
423
473
484
498
484
Total Equity
- -
45.57
43.96
55.23
32.66
23.35
10.74
2.08
- -
- -
Return on Invested Capital (%)
- -
48.38
46.78
59.52
34.23
23.08
10.89
2.02
- -
- -
Return on Capital (%)
- -
48.38
48
62.43
34.64
23.1
10.89
2.02
-2.76
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
600
600
600
Market Capitalization
185
223
211

Working Capital

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
437
304
353
Cash, Cash Equivalents & STI
286
247
230
Accounts Receivable, Net
103
28
88
Inventories
46
23
31
Total Current Liabilities
49
26
49
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38.53%
2.84%
Free Cash Flow
- -
-603.89%
-67.95%
Net Income, GAAP
- -
-65.76%
-240.2%
Sales/Revenue/Turnover
- -
-11.24%
-32.18%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
344
2024
- -
- -
214
2025
- -
- -
145

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.08
2024
- -
- -
0.02
2025
- -
- -
-0.02

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Modern Chinese Medicine Group Co., Ltd. (1643.HK) operates as an investment holding company primarily engaged in the research, development, manufacture, and sale of traditional Chinese medicine (TCM) products in the People's Republic of China. The company offers a range of proprietary TCM formulations and herbal products, including patented medicines such as Chuanbei Pipa Syrup for cough relief, pediatric health supplements under the brand name for respiratory and digestive issues, and adult wellness tonics targeting immunity and vitality; it also provides contract manufacturing services for third-party TCM brands and operates retail clinics for TCM consultations and dispensing. Headquartered in Foshan, Guangdong province, the company was founded in 2006 and focuses on the pharmaceutical and healthcare segments, serving consumer markets through distribution channels in mainland China with expansion into select Asian regions. In recent developments within the last two years, the company announced a strategic partnership with a leading e-commerce platform in 2024 to enhance online sales of its core TCM brands, completed a HK$150 million funding round in early 2025 to support new product R&D in pediatric TCM, and launched an innovative line of sugar-free herbal lozenges targeting urban millennials amid rising health consciousness post-pandemic. No major acquisitions, name changes, or reorganizations have been reported recently.